Related references
Note: Only part of the references are listed.Transduction properties of adenovirus serotype 35 vectors after intravenous administration into nonhuman primates
Fuminori Sakurai et al.
MOLECULAR THERAPY (2008)
Long-term outcome of phase I/II clinical trial of Ad-OC-TK/VAL gene therapy for hormone-refractory metastatic prostate cancer
Toshiro Shirakawa et al.
HUMAN GENE THERAPY (2007)
Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 candidate vaccine delivered by a replication-defective recombinant adenovirus vector
Andrew T. Catanzaro et al.
JOURNAL OF INFECTIOUS DISEASES (2006)
Angiogenic gene therapy in patients with nonrevascularizable ischemic heart disease:: a phase 2 randomized, controlled trial of AdVEGF121 (AdVEGF121) versus maximum medical treatment
D. J. Stewart et al.
GENE THERAPY (2006)
Intrahepatic injection of adenovirus reduces inflammation and increases gene transfer and therapeutic effect in mice
Julien Crettaz et al.
HEPATOLOGY (2006)
Adenovirus serotype 35 vector-mediated transduction into human CD46-transgenic mice
F. Sakurai et al.
GENE THERAPY (2006)
Phase I/II adenoviral p53 gene therapy for chemoradiation resistant advanced esophageal squamous cell carcinoma
Hideaki Shimada et al.
CANCER SCIENCE (2006)
Human CD46-transgenic mice in studies involving replication-incompetent adenoviral type 35 vectors
S Verhaagh et al.
JOURNAL OF GENERAL VIROLOGY (2006)
Adenovirus vectors based on human adenovirus type 19a have high potential for human muscle-directed gene therapy
C Thirion et al.
HUMAN GENE THERAPY (2006)
Immunogenicity of recombinant fiber-chimeric adenovirus serotype 35 vector-based vaccines in mice and rhesus monkeys
A Nanda et al.
JOURNAL OF VIROLOGY (2005)
Immunogenicity of heterologous prime-boost regimens involving recombinant adenovirus serotype 11 (Ad11) and Ad35 vaccine vectors in the presence of anti-Ad5 immunity
AAC Lemckert et al.
JOURNAL OF VIROLOGY (2005)
Hepatocyte-targeted gene transfer by combination of vascularly delivered plasmid DNA and in vivo electroporation
M Sakai et al.
GENE THERAPY (2005)
Intratumoral injection of INGN 241, a nonreplicating adenovector expressing the melanoma-differentiation associated gene-7 (mda-7/IL24): Biologic outcome in advanced cancer patients
AW Tong et al.
MOLECULAR THERAPY (2005)
Comparison of adenoviral and adeno-associated viral vectors for pancreatic gene delivery in vivo
AY Wang et al.
HUMAN GENE THERAPY (2004)
Replication-deficient human adenovirus type 35 vectors for gene transfer and vaccination:: Efficient human cell infection and bypass of preexisting adenovirus immunity
R Vogels et al.
JOURNAL OF VIROLOGY (2003)
Development of adenovirus serotype 35 as a gene transfer vector
PS Reddy et al.
VIROLOGY (2003)
Efficient gene transfer into human CD34+ cells by an adenovirus type 35 vector
F Sakurai et al.
GENE THERAPY (2003)
An investigation of adverse effects caused by the injection of high-dose TNFα-expressing adenovirus vector into established murine melanoma
Y Okada et al.
GENE THERAPY (2003)
Human adenovirus type 35: nucleotide sequence and vector development
W Gao et al.
GENE THERAPY (2003)
Characterization of in vitro and in vivo gene transfer proplefties of adenovirus serotype 35 vector
F Sakurai et al.
MOLECULAR THERAPY (2003)
Exploiting the natural diversity in adenovirus tropism for therapy and prevention of disease
MJE Havenga et al.
JOURNAL OF VIROLOGY (2002)
Enhanced antitumor effect and reduced vector dissemination with fiber-modified adenovirus vectors expressing herpes simplex virus thymidine kinase
H Mizuguchi et al.
CANCER GENE THERAPY (2002)